Clomifene citrate

• Product NameClomifene citrate
  CAS No.50-41-9
  Purity99%
  Min QuantityKilograms
  Price0~100
• View Contact Detail

• 
  Molecular Structure

Detailed Description

Clomifene citrate

Quick Details:
--------------------------------------------
Another name: 2-4-[2-Chloro-1,2-diphenylethenyl]phenoxy-N,N-diethylethanamine citrate
CAS NO: 50-41-9
Structural formula: C26H28ClNO C6H8O7
Molecular weight: 598.11
Appearance: white or milky white crystalline powder
Standard: CP USP
Use: the goods to anti-estrogen fertility inducer, the objects in dysfunctional uterine bleeding, polycystic ovary, menstrual disorders and drug-induced amenorrhea and other gynecologic diseases

Description:
---------------------------------------
Clomiphene citrate is a white to pale yellow, essentially odorless, crystalline powder. It is freely soluble in methanol; soluble in ethanol; slightly soluble in acetone, water, and chloroform; and insoluble in ether.

Clomiphene citrate tablets USP is a mixture of two geometric isomers [cis (zuClomiphene) and trans (enClomiphene)] containing between 30% and 50% of the cis-isomer.

Each white scored tablet contains 50 mg Clomiphene citrate USP. The tablet also contains the following inactive ingredients: corn starch, lactose, magnesium stearate, pregelatinized corn starch, and sucrose.

Indications and Usage for Clomiphene:
---------------------------------------

Clomiphene citrate tablets USP is indicated for the treatment of ovulatory dysfunction in women desiring pregnancy. Impediments to achieving pregnancy must be excluded or adequately treated before beginning Clomiphene citrate tablets USP therapy. Those patients most likely to achieve success with Clomiphene therapy include patients with polycystic ovary syndrome (see WARNINGS: Ovarian Hyperstimulation Syndrome), amenorrhea-galactorrhea syndrome, psychogenic amenorrhea, post-oral-contraceptive amenorrhea, and certain cases of secondary amenorrhea of undetermined etiology.

Properly timed coitus in relationship to ovulation is important. A basal body temperature graph or other appropriate tests may help the patient and her physician determine if ovulation occurred. Once ovulation has been established, each course of Clomiphene citrate tablets USP should be started on or about the 5th day of the cycle. Long-term cyclic therapy is not recommended beyond a total of about six cycles (including three ovulatory cycles). (See DOSAGE AND ADMINISTRATION and PRECAUTIONS.)

Side Effects:
---------------------------------------
Stomach upset, bloating, abdominal/pelvic fullness, flushing ("hot flashes"), breast tenderness, headache, or dizziness may occur. If any of these effects persist or worsen, notify your doctor or pharmacist promptly.

Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.

Tell your doctor immediately if any of these unlikely but serious side effects occur: abnormal vaginal bleeding, mental/mood changes.

Vision changes (e.g., blurred vision, seeing spots or flashes) may sometimes occur during clomiphene treatment, especially if you are exposed to bright light. These side effects usually go away a few days or weeks after treatment is stopped. However, in rare cases, vision changes may be permanent. Get medical help right away if any of the following occur: vision problems/changes, eye pain.
• 
• Clomifene citrate